spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  leukemia 


 Your search returned too many results! The most recent 500 items are shown below:
 HSMN NewsFeed - 14 Dec 2022
STORM Therapeutics announces closing of USD $30M Series B financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Sep 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2022
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 May 2022
Alercell Starts to Distribute Human Papilloma Virus (HPV) DNA Test
Diagnostics Product Launch
 HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2022
BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 28 Jan 2022
Blueprint Medicines' AYVAKYT(R) (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 25 Nov 2021
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2021
Kintara Announces Changes to Executive Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Dec 2020
Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel
 HSMN NewsFeed - 12 Oct 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2020
Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Aug 2020
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 May 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
Diagnostics Oncology FDA
 HSMN NewsFeed - 15 May 2020
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 20 Apr 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jan 2020
PANTHERx(R) Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 13 Dec 2019
Fluxion Launches Three New Spotlight(TM) Liquid Biopsy NGS Panels
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2019
Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2019
ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth
Diagnostics Personnel
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Dec 2018
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 Nov 2018
HemoScreen(TM) Hematology Analyzer for Point of Care, Receives FDA 510(k) Clearance
Devices Diagnostics FDA
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 6 Sep 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2018
Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Aug 2018
Siklos(R), the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 16 Aug 2018
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Aug 2018
Endo Announces Appointment of Laure Park as Senior Vice President, Investor Relations and Corporate Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Jun 2018
Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2018
Forty Seven Inc. Appoints Ian T. Clark to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Apr 2018
Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2018
Roche launches the new cobas m 511 analyzer, signaling a new era in hematology testing
Diagnostics FDA Product Launch
 HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 2 Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Feb 2018
Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2018
Geoffrey B. Davis Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jan 2018
Abbott Launches Alinity(TM) h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration
Devices Diagnostics Product Launch
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2017
OncoTartis Closes $6M Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 6 Dec 2017
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 4 Dec 2017
Mylan and Aspen Announce Launch of Generic Busulfex(R) Injection
Biopharmaceuticals Oncology Generics Product Launch
 HSMN NewsFeed - 17 Nov 2017
Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Biopharmaceuticals Devices Drug Delivery Product Launch
 HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Aug 2017
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
Biopharmaceuticals
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2017
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
Regenerative Medicine Neurology
 HSMN NewsFeed - 22 Jun 2017
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2017
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
Regenerative Medicine Neurosurgery
 HSMN NewsFeed - 28 Apr 2017
Invivoscribe(R) Receives FDA Approval for the LeukoStrat(R) CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt(R) and is the First Companion Diagnostic for AML
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Apr 2017
FDA Approves XATMEP(TM), the First and Only Ready-To-Use Methotrexate Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Apr 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2017
OncoResponse Announces Final Closing of $22.5M Series A Financing Round
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2016
Northern Biologics, Mosaic Biomedicals Execute Transformative Deal
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox(R) for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Sep 2016
Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Sep 2016
Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Aug 2016
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2016
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
Biopharmaceuticals Distribution
 HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2016
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 1 Jun 2016
Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Apr 2016
Celator(R) Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS(TM) Compared to Standard Treatment for Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 14 Mar 2016
ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Feb 2016
Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 4 Feb 2016
Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2015
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2015
European Commission Approves Amgen's IMLYGIC(TM) (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2015
Syros Pharmaceuticals Appoints David A. Roth, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Amgen's BLINCYTO(R) (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2015
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin(TM) (ubenimex) for Inflammatory Diseases Involving LTB4
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Nov 2015
New CyberKnife(R) and TomoTherapy(R) System Data Presented at Leading Scientific Industry Meeting
Devices Oncology
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 2 Sep 2015
ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Aug 2015
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Aug 2015
Cantex Pharmaceuticals Enhances Executive Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Jul 2015
Xencor Appoints Yujiro S. Hata to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2014
NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2014
Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Aug 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jun 2014
ARIAD Announces Three Key Appointments to Its Global Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2014
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Apr 2014
FDA Approves New Liquid Form Of Treatment For Patients With Acute Lymphoblastic Leukemia (ALL) As Part Of A Combination Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2014
Actinium Announces Key Additions to Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Apr 2014
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2014
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2014
Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2014
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Feb 2014
Avillion Appoints Dr Allison Jeynes-Ellis as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2014
Zocere Appoints Zavitz as Chief Scientific Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jan 2014
Igenica Raises $14 Million in Additional Series C Funding to Advance Product Pipeline and Technology Platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jan 2014
Biothera Names VP of Biomarker Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jan 2014
AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jan 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 13 Jan 2014
Galena Biopharma Acquires Mills Pharmaceuticals, LLC
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Jan 2014
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2013
Senesco Announces Letter of Intent to Merge with Fabrus
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Dec 2013
Cancer Genetics, Inc. Strengthens Its Diagnostics Sales Team With Seasoned Industry Leader
Diagnostics Oncology Personnel
 HSMN NewsFeed - 2 Dec 2013
Lorus Therapeutics Completes New Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Nov 2013
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2013
ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 18 Oct 2013
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Oct 2013
Pfizer Receives European Approval For Label Update Regarding The Use Of Prevenar 13 In Certain High-Risk Populations
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2013
Loxo Oncology Raises $33 Million in Series A Financing to Fund Development of Small Molecule Oncology Drugs
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Sep 2013
Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2013
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jul 2013
SynGen Hires Former Pall Medical Executive as President of Cord Blood Business Unit
Devices Regenerative Medicine Personnel
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2013
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jul 2013
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jul 2013
Sequenta Completes $20 Million Series C Financing
Diagnostics Oncology Venture Capital Personnel
 HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Jun 2013
Teva’s Lonquex(R)(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 May 2013
Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
Biopharmaceuticals Litigation
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 24 Apr 2013
Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2013
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2013
Acceleron Receives Two FDA Orphan Designations for ACE-536
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2013
Clinigen Group plc Acquires Oncology Support Therapy Cardioxane(R) from a World-Leading Pharmaceutical Company
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 25 Mar 2013
Arzerra Receives Approval in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2013
bioTheranostics Adds Chief Medical Officer & Vice President of Medical, Clinical & Regulatory Affairs
Diagnostics Oncology Personnel
 HSMN NewsFeed - 4 Mar 2013
Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer
Diagnostics Personnel
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Feb 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 30 Jan 2013
MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jan 2013
New NCCN Guidelines for Patients(R) Available for Adolescents and Young Adults with Cancer
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Dec 2012
Amarantus BioScience Acquires Neurodegenerative Diagnostic Intellectual Property Portfolio from Power3 Medical Products
Biopharmaceuticals Diagnostics Neurology Acquisitions
 HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Nov 2012
Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
Diagnostics Oncology
 HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2012
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 8 Nov 2012
90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
Devices Oncology
 HSMN NewsFeed - 29 Oct 2012
Combination of Surgery and Adjuvant Radiation Treatment Shows Improved Survival for Elderly Women With Early-Stage Breast Cancer
Devices Oncology
 HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Oct 2012
Clinical Study Validates Sequenta’s LymphoSIGHT(TM) Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection
Diagnostics Oncology
 HSMN NewsFeed - 11 Oct 2012
Zyngenia, Inc. Expands Its Board of Directors with Leading Life Sciences Business Executives Christian Itin and Jason Rhodes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2012
Sunesis Pharmaceuticals Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Sep 2012
Cialis(R) (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 21 Sep 2012
Actinium Pharmaceuticals Announces New Round of Financing
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Regenerative Medicine Oncology
 HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Aug 2012
Actinium Pharmaceuticals Strengthens Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2012
Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer
Devices Oncology Surgery
 HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2012
Formula Pharmaceuticals Appoints Morton Collins to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 May 2012
Talon Therapeutics Appoints Head of Commercial Operations and Planning
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 1 May 2012
Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company's Scientific Advisory Board
Diagnostics Personnel
 HSMN NewsFeed - 27 Apr 2012
New Drug Application for Arzerra Submitted in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 26 Apr 2012
Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers
Biopharmaceuticals Oncology Personalized Medicine
 HSMN NewsFeed - 25 Apr 2012
Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2012
Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
Diagnostics Personnel
 HSMN NewsFeed - 16 Apr 2012
Mayo Clinic Breast Cancer Study Finds New Type of Mutation
Diagnostics Oncology
 HSMN NewsFeed - 28 Mar 2012
Raptor Pharmaceutical Corp. Announces the Appointment of Henk Doude van Troostwijk as General Manager of European Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2012
TetraLogic Pharmaceuticals Appoints C. Glenn Begley as Senior Vice President Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2012
Bellicum Closes $20 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Feb 2012
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 7 Feb 2012
New Study Evaluates Cialis(R) in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 2 Feb 2012
Ronnie Andrews Joins Life Technologies as President, Medical Sciences
Diagnostics Personnel
 HSMN NewsFeed - 2 Feb 2012
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC(R) for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 26 Jan 2012
Celgene to Acquire Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2011
Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 6 Dec 2011
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2011
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Diagnostics FDA
 HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Oct 2011
Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2011
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2011
TrovaGene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia
Diagnostics Licensing Oncology
 HSMN NewsFeed - 6 Sep 2011
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials With A New Brain Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Sep 2011
Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA
 HSMN NewsFeed - 8 Aug 2011
Researchers Find RapidArc(R) Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
Devices Oncology
 HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
Oncology
 HSMN NewsFeed - 28 Jul 2011
Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2011
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2011
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2011
NanoBio(R) Appoints Peter Ulrich to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital
 HSMN NewsFeed - 23 Mar 2011
Asuragen Launches CE Marked IVD AmplideX(TM) Fragile X Test in Europe
Diagnostics Regulatory
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2011
Sunesis Receives FDA Fast Track Designation for Vosaroxin in AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2011
Cellerant Therapeutics Announces Key Additions to Sr. Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2011
Optimer Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2010
Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2010
GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.
Diagnostics Personalized Medicine Mergers & Acquisitions
 HSMN NewsFeed - 20 Oct 2010
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Sep 2010
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
Regenerative Medicine FDA
 HSMN NewsFeed - 13 Sep 2010
Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Aug 2010
FDA Approves Innovative Liver Cell Therapy for Clinical Trial in the U.S.
Regenerative Medicine FDA
 HSMN NewsFeed - 4 Aug 2010
Gemin X Closes $8 Million Series E Financing
Biopharmaceuticals Venture Capital Oncology
 HSMN NewsFeed - 28 Jul 2010
EpiCept Amends Employment Agreement and Completes Severance Agreements with Executive Officers
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2010
Clarient Announces Publication of Mammostrat(R) Breast Cancer Study in Breast Cancer Research
Diagnostics Oncology
 HSMN NewsFeed - 6 Jul 2010
EpiCept Corporation Names Rita Kelley Senior Director of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Apr 2010
Manhattan Scientifics' Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram
Devices Oncology
 HSMN NewsFeed - 20 Apr 2010
Gemin X Announces $16 Million Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2010
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 22 Mar 2010
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
Diagnostics Oncology Distribution
 HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2010
New Data Indicate Effectiveness of Clarient's Ovotax(TM) Test for Ovarian Cancer
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 12 Mar 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2010
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2010
Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment
Biopharmaceuticals Diagnostics Oncology Acquisitions
 HSMN NewsFeed - 23 Feb 2010
Aldagen Announces Strategic Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2010
Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Regenerative Medicine Oncology
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 15 Jan 2010
IRX Therapeutics Appoints Neil L. Berinstein Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
Meda In-Licenses Exclusive Rights To Ceplene
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Dec 2009
Vion Pharmaceuticals Announces FDA Conclusion
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2009
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2009
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 18 Nov 2009
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Diagnostics Oncology Distribution
 HSMN NewsFeed - 16 Nov 2009
Fate Therapeutics Closes $30 Million Series B Financing
Regenerative Medicine Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Nov 2009
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2009
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2009
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
Diagnostics Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2009
Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Aug 2009
APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jul 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., To Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jul 2009
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2009
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2009
Clovis Oncology Raises $145 Million in Start-Up Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 7 May 2009
Ipsogen Launches a New Test to Guide Hormonotherapy Prescription in Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 May 2009
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2009
Pixantrone Now Available in Europe on a Named-Patient Basis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 May 2009
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
Diagnostics Oncology
 HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2009
EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
CytRx's Arimoclomol Demonstrates Statistically Significant Neurorestorative Results in a Preclinical Embolic Stroke Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 6 Mar 2009
FDA Appeal Decision Indicates that Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Mar 2009
European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Feb 2009
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  

 Additional items found! 500

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 500 additional stories matching:
leukemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.